Merck: Marches Forward, One of The Best Big Pharma Picks Of 2023 (NYSE:MRK)
Merck's Q1 2023 earnings exceeded expectations, bolstered by blockbuster drugs Keytruda and Gardasil, with a raised FY23 outlook. See why MRK stock is a Buy.
Solskin
Post earnings update to thesis
We maintain a buy rating on Merck (NYSE: MRK) after Q1 2023 earnings that exceeded our expectations, showcasing robust ...
Read More
Other Stories in Business
- Gene Munster Says Apple's 'Mess Wasn't As Big As It Looked' As iPhone Maker Delivers Better Than Expected Results - Apple (NASDAQ:AAPL)
- Wealthsimple Visa Infinite (beta launch)
- » Making money blogging about lifestyle design Early Retirement Extreme: — a combination of simple living, anticonsumerism, DIY ethics, self-reliance, resilience, and applied capitalism
- US extends greetings to India on 76th Republic Day
- Trump's Canada, Mexico Tariff Threat Aimed At Gaining Leverage In Trade Talks: Experts
- US Fed Prepares To Pause In First Rate Decision Since Trump's Inauguration
- Sasakawa Leprosy Initiative to Boost Support for Indonesia
- JPMorgan’s Kevin Willsey retires after over 30 years at Wall Street’s largest bank
- Watch These Bitcoin Price Levels After Inauguration Day Volatility
